コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 -reperfusion-injured adult nonobese diabetic-severe combined immunodeficient mice.
2 gnals as shown in chimeric nonobese diabetic/severe combined immunodeficient mice.
3 LAPC-4 cells were injected into male severe combined immunodeficient mice.
4 antation into the mammary fat pads of female severe combined immunodeficient mice.
5 ndrogen-independent DU145 prostate cancer in severe combined immunodeficient mice.
6 MET-1 leukemic cells into nonobese diabetic/severe combined immunodeficient mice.
7 s when these cells were inoculated s.c. into severe combined immunodeficient mice.
8 into cardiomyocytes in the injured hearts of severe combined immunodeficient mice.
9 ) from an ATL patient into nonobese diabetic/severe combined immunodeficient mice.
10 colonization potential after injection into severe combined immunodeficient mice.
11 by a neutralizing antibody to human CXCR4 in severe combined immunodeficient mice.
12 econstitute the marrow of non-obese diabetic severe combined immunodeficient mice.
13 ited lung colonization of the tumor cells in severe combined immunodeficient mice.
14 nt tumor shrinkage of melanoma xenografts in severe combined immunodeficient mice.
15 lets were transplanted in nonobese diabetic, severe combined immunodeficient mice.
16 artery was performed by thermal ligation in severe combined immunodeficient mice.
17 al vector expressing SDF1alpha (AdSDF1) into severe combined immunodeficient mice.
18 urgical specimens and grown as xenografts in severe combined immunodeficient mice.
19 f tumorigenicity after s.c. inoculation into severe combined immunodeficient mice.
20 n into the left subrenal capsule of diabetic severe combined immunodeficient mice.
21 mary fat pad tumors or distant metastases in severe combined immunodeficient mice.
22 to form colonies in soft agar and tumors in severe combined immunodeficient mice.
23 .c. injection of human melanoma LOX cells in severe combined immunodeficient mice.
24 overt AML-like disease in nonobese diabetic--severe combined immunodeficient mice.
25 implanted into the right ovarian pedicle of severe combined immunodeficient mice.
26 ents were performed with tumor xenografts in severe combined immunodeficient mice.
27 del with a composite skin model also made on severe combined immunodeficient mice.
28 s the growth of human soft-tissue sarcoma in severe combined immunodeficient mice.
29 ll lymphoma and multiple myeloma xenografted severe combined immunodeficient mice.
30 lized to infiltrating leukocytes in diseased severe combined immunodeficient mice.
31 ression was studied in nonobese diabetic and severe combined immunodeficient mice.
32 ransparent dorsal skin-fold chambers in male severe combined immunodeficient mice.
33 d immunodeficient mice or non-obese diabetic/severe combined immunodeficient mice.
34 leukemia in vitro and suppress its growth in severe combined immunodeficient mice.
35 in slowing human myeloid leukemia growth in severe combined immunodeficient mice.
36 cells in transparent dorsal skin windows in severe combined immunodeficient mice.
37 low TF and VEGF producer, were grown s.c. in severe combined immunodeficient mice.
38 or, which was injected into the tail vein of severe combined immunodeficient mice.
39 Ak-positive) and LS174T tumor-bearing BALB/c severe combined immunodeficient mice.
40 nd A-2 human prostatic cancers when grown in severe combined immunodeficient mice.
41 n experimental cryptococcosis in outbred and severe combined immunodeficient mice.
42 hibits growth of a human breast carcinoma in severe combined immunodeficient mice.
43 in a transparent dorsal skin fold chamber in severe combined immunodeficient mice.
44 ent and lost their ability to form tumors in severe combined immunodeficient mice.
45 we implanted human-derived glioma cells into severe combined immunodeficient mice.
46 No airway hyperractivity occurred in severe combined immunodeficient mice.
47 40L-deficient animals prevented infection in severe combined immunodeficient mice.
48 ling of human coronary artery transplants in severe combined immunodeficient mice.
49 nd also in tumors in prostate-tumor-bearing, severe combined immunodeficient mice.
50 or supplemented (GFS) matrigel into diabetic severe combined immunodeficient mice.
51 reotactically injected into the subcortex of severe combined immunodeficient mice.
52 tail vein of MDA-MB-231 tumor-bearing female severe combined immunodeficient mice.
53 sed invasiveness of MCF10.DCIS xenografts in severe combined immunodeficient mice.
54 ng highly invasive HCC in nonobese diabetic, severe combined immunodeficient mice.
55 raftment of these cells in nonobese diabetic/severe combined immunodeficient mice.
56 tumor formation and inhibited metastasis in severe combined immunodeficient mice.
57 nt growth in soft agar, and tumorigenesis in severe combined immunodeficient mice.
58 an carcinomas implanted in immunocompromised severe combined immunodeficient mice.
59 ity in prostate cancer tumors implanted into severe combined immunodeficient mice.
60 sicles in a model of glycerol-induced AKI in severe combined immunodeficient mice.
61 ompetitive repopulation of nonobese diabetic/severe combined immunodeficient mice.
62 homa cells were intravitreally injected into severe combined immunodeficient mice.
63 ction on PLC/PRF/5 human tumor xenografts in severe combined immunodeficient mice.
64 in soft agar as well as s.c. tumor growth in severe combined immunodeficient mice.
65 on, led to the formation of larger tumors in severe combined immunodeficient mice.
66 mor cell growth and invasion in vitro and in severe combined immunodeficient mice.
67 and these cells were grown as xenografts in severe combined immunodeficient mice.
68 f resistant multiple myeloma tumors (MM1) in severe combined immunodeficient mice.
69 tibody targeted to HER2-expressing tumors in severe combined immunodeficient mice.
70 variant of SN12C) tumors grown in kidneys of severe combined immunodeficient mice.
71 cells were injected intratibially in C3H and severe-combined immunodeficient mice.
72 C1 was seen toward H460 tumor xenografts in severe-combined immunodeficient mice.
73 te could be transplanted to irradiated SCID (severe combined immunodeficient) mice.
74 eotide-binding oligomerization domain)/SCID (severe combined immunodeficient) mice.
75 edium before transfer to Prkdc(scid)-mutant (severe combined immunodeficient) mice.
76 line (EGI-1) after xenotransplantation into severe-combined-immunodeficient mice, (3) expression of
77 cause combined therapy is not efficacious in severe combined immunodeficient mice; (3) the rejection
78 model originating from footpad injection in severe combined immunodeficient mice, 95% of the resulti
79 antation of these cells in nonobese diabetic-severe combined immunodeficient mice (a) generated xenog
81 ntitumor effects were markedly diminished in severe combined immunodeficient mice and (b) CD8+ T cell
83 laxis to hu-peripheral blood leukocyte (PBL)-severe combined immunodeficient mice and chimpanzees.
85 l blood leukocytes (PBL) were implanted into severe combined immunodeficient mice and infected with h
87 nted tumors when transplanted into syngeneic severe combined immunodeficient mice and normal mice.
88 MDMs were injected into the basal ganglia of severe combined immunodeficient mice and then Li was adm
89 owth of malignant mesothelioma xenografts in severe-combined immunodeficient mice and extended host s
90 ere injected directly into the peritoneum of severe combined immunodeficient mice, and in a syngeneic
91 neither resulted in weight loss nor death in severe combined immunodeficient mice, and pock lesions w
92 s were implanted into the cranial windows in severe combined immunodeficient mice, and VEGF promoter
93 ation in soft agar, tumor formation in SCID (severe combined immunodeficient) mice, and adhesion.
95 uman skin is orthotopically transferred onto severe combined immunodeficient mice, autologous immunoc
96 vir had marked antitumor efficacy in vivo in severe combined immunodeficient mice bearing A2780OSP-1-
98 e studied the effects of THMAM-MD in vivo in severe combined immunodeficient mice bearing HT-29 colon
100 "coaguligand." After i.v. administration to severe combined immunodeficient mice bearing human Hodgk
102 ncer and significantly prolonged survival of severe combined immunodeficient mice bearing LAPC-4 xeno
103 activity of 8H9(scFv)-PE38 was evaluated in severe combined immunodeficient mice bearing MCF-7 breas
105 se implant delivery of 4-hydroxytamoxifen to severe combined immunodeficient mice bearing Rat-1-MycER
109 PET/CT small-animal imaging was performed in severe combined immunodeficient mice bearing solid and d
111 g 125I- and (131)I-labeled CTX injected into severe combined immunodeficient mice bearing xenografted
112 the growth of TPras transgenic melanomas in severe combined immunodeficient mice, blocked invasive b
113 -gamma had a markedly reduced growth rate in severe combined immunodeficient mice, but IFN-gamma did
114 which can be transmitted to naive syngeneic severe combined immunodeficient mice by adoptive transfe
115 e drug combination decreased tumor volume in severe combined immunodeficient mice by approximately 60
116 totally interrupted the infection of hu-PBL-severe combined immunodeficient mice by PBL-grown HIV-1
117 fts in three genetically isolated strains of severe combined immunodeficient mice (C.B-17, C57BL/6J,
118 model established by tail vein injection in severe combined immunodeficient mice, clonality of lung
119 growth and the gain in mean tumor volume in severe combined immunodeficient mice compared with vehic
122 nd engraft immunodeficient nonobese diabetes/severe combined immunodeficient mice during both primary
125 Spleen cells from normal and nude, but not severe combined immunodeficient mice, exhibited strong p
126 6Mre11(ATLD1/ATLD1) and C57BL/6(Prkdc/SCID) (severe combined immunodeficient) mice exposed to low-dos
127 cific neutralizing anti-CXCL12 antibodies to severe combined immunodeficient mice expressing human no
128 ether with normal BALB/c B cells into C.B-17 severe combined immunodeficient mice failed to generate
130 on of late-passage H-Ras-expressing cells in severe combined immunodeficient mice formed carcinomas w
131 eplication in nontumor tissues and protected severe combined immunodeficient mice from developing let
132 was used in vivo to treat nonobese diabetic/severe combined immunodeficient mice given injections of
134 2F LMP transfectants were non-tumorigenic in severe combined immunodeficient mice, HaCaT LMP transfec
136 uction of the human HGF ligand in transgenic severe combined immunodeficient mice (hHGF(tg)-SCID mice
137 odinated, and their clearance was studied in severe combined immunodeficient mice hosts by whole-body
138 d not express uPAR formed palpable tumors in severe combined immunodeficient mice; however, metastase
140 he marrow space of the bone implanted in the severe combined immunodeficient mice implanted with feta
141 0530 profoundly inhibits tumor metastasis in severe combined immunodeficient mice implanted with GRP-
142 opic HIV-1(JR-CSF) isolate (JR-CSF mice) and severe combined immunodeficient mice implanted with huma
144 nst both PC-3 and DU-145 tumor xenografts in severe combined immunodeficient mice in a dose-dependent
147 CDV) and octadecyloxyethyl-CVD (ODE-CDV)--in severe combined immunodeficient mice in which either hum
148 sgene expression was substantially higher in severe combined immunodeficient mice, indicating that in
149 as far less efficacious in immunocompromised severe combined immunodeficient mice, indicating the req
150 5(+) T cells to infected macrophage-depleted severe combined immunodeficient mice induced CNS demyeli
151 ionship between phospho-AKT and FAS in vivo, severe combined immunodeficient mice injected intraperit
152 meliorated adoptively transferred ileitis in severe combined immunodeficient mice injected with CD4 +
153 the agents, named TH-1177, was used to treat severe combined immunodeficient mice inoculated with the
155 to repopulate human bone grafts implanted in severe combined immunodeficient mice, MSCV-directed NGFR
158 nder the kidney capsule of nonobese diabetic-severe combined immunodeficient mice (n=4-7 per group/ti
161 dies, BMSCs and ECs were cotransplanted into severe combined immunodeficient mice on biodegradable po
163 t study, we induced EAE in T-cell-deficient, severe combined immunodeficient mice or in immunocompete
164 ting factor, and stem cell factor genes with severe combined immunodeficient mice or non-obese diabet
165 the administration of TNF-alpha to infected severe combined immunodeficient mice or to infected cult
169 macrophages (MDMs) into the basal ganglia of severe combined immunodeficient mice recapitulates histo
170 ally injected into the basal ganglia of CB17 severe combined immunodeficient mice, received daily int
171 th a targeted deletion of the T-bet gene and severe combined immunodeficient mice receiving CD4+ cell
172 er growth was evaluated in hu-PBL-SCID mice (severe combined immunodeficient mice reconstituted with
174 ed in the dorsal skinfold chamber in C3H and severe combined immunodeficient mice, respectively, and
175 uman ovarian tumor cells into the ovaries of severe combined immunodeficient mice resulted in periton
176 mum tolerated dose of 2L-Rap-hLL1-gamma4P in severe combined immunodeficient mice (SCID) or BALB/c mi
177 infection in human intestinal xenografts in severe combined immunodeficient mice (SCID-HU-INT mice).
178 racranial implantation of human gliomas into severe combined immunodeficient mice showed a marked red
179 The standard adoptive transfer study in NOD-severe combined immunodeficient mice showed that periphe
180 nts using a human pancreatic cancer model in severe combined immunodeficient mice showed that there w
181 Split-thickness pig skin was transplanted on severe combined immunodeficient mice so that pig dermal
182 silicone chambers implanted on the backs of severe combined immunodeficient mice sorts out to recons
184 LAPC-9) propagated by serial passage in male severe combined immunodeficient mice that expresses pros
186 severity of HSK in CD4+ T cell-reconstituted severe combined immunodeficient mice that were depleted
187 following immunization of nonobese diabetic-severe combined immunodeficient mice that were repopulat
190 When injected into the mammary fat pads of severe combined immunodeficient mice, the tumors formed
193 an peripheral blood leukocytes (hu PBL-SCID [Severe Combined Immunodeficient] mice) to test the hypot
194 marrow of human bones that were implanted in severe combined immunodeficient mice, tumors formed by c
196 demonstrated that less neovascularization in severe combined immunodeficient mice was observed with c
198 tion of human fetal thymus/liver implants in severe combined immunodeficient mice was used to investi
200 Finally, using an angiogenesis assay in severe combined immunodeficient mice, we demonstrate tha
201 lls, bone marrow chimeras, and reconstituted severe combined immunodeficient mice, we identify the pr
202 and adoptive transfer of CD4(+) T cells into severe combined immunodeficient mice, we show that anti-
203 drogen-dependent Shionogi carcinoma grown in severe combined immunodeficient mice, we show that castr
204 igh-avidity CTLs adoptively transferred into severe combined immunodeficient mice were 100- to 1000-f
205 cells harvested from carcinoma formation in severe combined immunodeficient mice were designated caM
207 cific cellular and humoral immune responses, severe combined immunodeficient mice were given an adopt
212 tin-expressing tumors grown as xenografts in severe combined immunodeficient mice were responsive to
215 atalase was also seen in tumor xenografts in severe combined immunodeficient mice when compared with
216 human stem cell-engrafted nonobese diabetic/severe combined immunodeficient mice, where 24% of the h
217 sfectants produced no intracranial tumors in severe combined immunodeficient mice, whereas parental U
218 by analyzing early passage fibroblasts from severe combined immunodeficient mice, which are deficien
219 et organs of immunocompetent BALB/c mice and severe combined immunodeficient mice, which are exquisit
221 ive, Fc-dependent, passive immunity, even in severe combined immunodeficient mice with an established
224 in situ zymography, in colonic tissues from severe combined immunodeficient mice with colitis induce
225 inst subcutaneous B-cell tumor xenografts in severe combined immunodeficient mice with comparable or
226 KLMS-1 and rhabdomyosarcoma RD xenografts in severe combined immunodeficient mice with DC101 resulted
227 dementia, dexamethasone was administered to severe combined immunodeficient mice with HIV-1 encephal
228 HCV-infected urokinase plasminogen activator-severe combined immunodeficient mice with livers repopul
229 ficient NOD/SCID (nonobese diabetic/X-linked severe combined immunodeficient) mice with human cord bl
230 ation of SKOV3ip1 cells in nonobese diabetic/severe combined immunodeficient mice, with increased pho
231 cell lines grow as solitary nodules in nude/severe combined immunodeficient mice without manifesting
233 asion assays, and/or injected into flanks of severe combined immunodeficient mice; xenograft tumor gr
234 Furthermore, Kp-10 inhibits tumor growth in severe combined immunodeficient mice xenografted with hu
236 volume, rate of metastasis, and mortality of severe combined immunodeficient mice xenografted with PC
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。